Literature DB >> 24067982

Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus.

Jing Gao1, Guangwen Lu, Jianxun Qi, Yan Li, Ying Wu, Yao Deng, Heyuan Geng, Hongbin Li, Qihui Wang, Haixia Xiao, Wenjie Tan, Jinghua Yan, George F Gao.   

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) recently emerged as a severe worldwide public health concern. The virus is highly pathogenic, manifesting in infected patients with an approximately 50% fatality rate. It is known that the surface spike (S) proteins of coronaviruses mediate receptor recognition and membrane fusion, thereby playing an indispensable role in initiating infection. In this process, heptad repeats 1 and 2 (HR1 and HR2) of the S protein assemble into a complex called the fusion core, which represents a key membrane fusion architecture. To date, however, the MERS-CoV fusion core remains uncharacterized. In this study, we performed a series of biochemical and biophysical analyses characterizing the HR1/HR2 complexes of this novel virus. The HR sequences were variably truncated and then connected with a flexible amino acid linker. In each case, the recombinant protein automatically assembled into a trimer in solution, displaying a typical α-helical structure. One of these trimers was successfully crystallized, and its structure was solved at a resolution of 1.9 Å. A canonical 6-helix bundle, like those reported for other coronaviruses, was revealed, with three HR1 helices forming the central coiled-coil core and three HR2 chains surrounding the core in the HR1 side grooves. This demonstrates that MERS-CoV utilizes a mechanism similar to those of other class I enveloped viruses for membrane fusion. With this notion, we further identified an HR2-based peptide that could potently inhibit MERS-CoV fusion and entry by using a pseudotyped-virus system. These results lay the groundwork for future inhibitory peptidic drug design.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24067982      PMCID: PMC3838252          DOI: 10.1128/JVI.02433-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Protein design of an HIV-1 entry inhibitor.

Authors:  M J Root; M S Kay; P S Kim
Journal:  Science       Date:  2001-02-02       Impact factor: 47.728

2.  Functional importance of the coiled-coil of the Ebola virus glycoprotein.

Authors:  S Watanabe; A Takada; T Watanabe; H Ito; H Kida; Y Kawaoka
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Pushing the boundaries of molecular replacement with maximum likelihood.

Authors:  R J Read
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2001-09-21

Review 4.  Mechanisms of viral membrane fusion and its inhibition.

Authors:  D M Eckert; P S Kim
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

5.  Enfuvirtide for prophylaxis against HIV infection.

Authors:  Lise Cuzin; Muriel Alvarez
Journal:  N Engl J Med       Date:  2003-11-27       Impact factor: 91.245

6.  Inhibition of HIV-1 infection by an intramolecular antisense peptide to T20 in gp160.

Authors:  M Imai; N Okada; H Okada
Journal:  Microbiol Immunol       Date:  2000       Impact factor: 1.955

7.  Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.

Authors:  Berend Jan Bosch; Byron E E Martina; Ruurd Van Der Zee; Jean Lepault; Bert Jan Haijema; Cees Versluis; Albert J R Heck; Raoul De Groot; Albert D M E Osterhaus; Peter J M Rottier
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-18       Impact factor: 11.205

8.  LearnCoil-VMF: computational evidence for coiled-coil-like motifs in many viral membrane-fusion proteins.

Authors:  M Singh; B Berger; P S Kim
Journal:  J Mol Biol       Date:  1999-07-30       Impact factor: 5.469

9.  Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors.

Authors:  Jieqing Zhu; Gengfu Xiao; Yanhui Xu; Fang Yuan; Congyi Zheng; Yueyong Liu; Huimin Yan; David K Cole; John I Bell; Zihe Rao; Po Tien; George F Gao
Journal:  Biochem Biophys Res Commun       Date:  2004-06-18       Impact factor: 3.575

10.  Structural basis for coronavirus-mediated membrane fusion. Crystal structure of mouse hepatitis virus spike protein fusion core.

Authors:  Yanhui Xu; Yiwei Liu; Zhiyong Lou; Lan Qin; Xu Li; Zhihong Bai; Hai Pang; Po Tien; George F Gao; Zihe Rao
Journal:  J Biol Chem       Date:  2004-04-27       Impact factor: 5.157

View more
  97 in total

1.  The amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents.

Authors:  Yang Yang; Yao Deng; Bo Wen; Huijuan Wang; Xin Meng; Jiaming Lan; George F Gao; Wenjie Tan
Journal:  Viral Immunol       Date:  2014-12       Impact factor: 2.257

2.  Peptide-Based Antiviral Drugs.

Authors:  N Arul Murugan; K Muruga Poopathi Raja; N T Saraswathi
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.

Authors:  Yufei Wang; Wanbo Tai; Jie Yang; Guangyu Zhao; Shihui Sun; Chien-Te K Tseng; Shibo Jiang; Yusen Zhou; Lanying Du; Jimin Gao
Journal:  Hum Vaccin Immunother       Date:  2017-03-09       Impact factor: 3.452

4.  Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.

Authors:  Shan Su; Yun Zhu; Sheng Ye; Qianqian Qi; Shuai Xia; Zhenxuan Ma; Fei Yu; Qian Wang; Rongguang Zhang; Shibo Jiang; Lu Lu
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

Review 5.  Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease.

Authors:  Jasper F W Chan; Susanna K P Lau; Kelvin K W To; Vincent C C Cheng; Patrick C Y Woo; Kwok-Yung Yuen
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

6.  A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein.

Authors:  Lanying Du; Guangyu Zhao; Yang Yang; Hongjie Qiu; Lili Wang; Zhihua Kou; Xinrong Tao; Hong Yu; Shihui Sun; Chien-Te K Tseng; Shibo Jiang; Fang Li; Yusen Zhou
Journal:  J Virol       Date:  2014-04-09       Impact factor: 5.103

Review 7.  MERS-CoV spike protein: a key target for antivirals.

Authors:  Lanying Du; Yang Yang; Yusen Zhou; Lu Lu; Fang Li; Shibo Jiang
Journal:  Expert Opin Ther Targets       Date:  2016-12-21       Impact factor: 6.902

8.  Receptor variation and susceptibility to Middle East respiratory syndrome coronavirus infection.

Authors:  Arlene Barlan; Jincun Zhao; Mayukh K Sarkar; Kun Li; Paul B McCray; Stanley Perlman; Tom Gallagher
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

Review 9.  Structure, Function, and Evolution of Coronavirus Spike Proteins.

Authors:  Fang Li
Journal:  Annu Rev Virol       Date:  2016-08-25       Impact factor: 10.431

10.  Identification of the Fusion Peptide-Containing Region in Betacoronavirus Spike Glycoproteins.

Authors:  Xiuyuan Ou; Wangliang Zheng; Yiwei Shan; Zhixia Mu; Samuel R Dominguez; Kathryn V Holmes; Zhaohui Qian
Journal:  J Virol       Date:  2016-05-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.